Ashraf Sadaf, Mapp Paul I, Walsh David A
Arthritis Research UK Pain Centre, Department of Academic Rheumatology, University of Nottingham, Nottingham, UK.
Arthritis Rheum. 2010 Jul;62(7):1890-8. doi: 10.1002/art.27462.
To determine whether blood vessel growth at the onset of resolving synovitis leads to its subsequent persistence and whether inhibiting this angiogenesis at the onset of persistent inflammation leads to its subsequent resolution.
Inflammation and angiogenesis were induced by injection of 0.03% carrageenan and/or 6 pmoles of fibroblast growth factor 2 (FGF-2) into rat knees. A brief treatment with the angiogenesis inhibitor PPI-2458 (5 mg/kg orally on alternate days) was administered 1 day before and up to 3 days after synovitis induction. Controls comprised naive and vehicle-treated rats. Synovial angiogenesis was measured using the endothelial cell proliferation index, and inflammation was determined by measuring joint swelling and macrophage percentage area. Data are presented as the geometric mean (95% confidence interval).
Intraarticular injection of 0.03% carrageenan into rat knees produced acute synovitis, which was not associated with synovial angiogenesis and which resolved within 29 days. Injection of FGF-2 (6 pmoles) induced synovial angiogenesis without significant synovitis. Stimulation of angiogenesis with FGF-2 at the time of carrageenan injection was followed by synovitis that persisted for 29 days. Persistence of carrageenan/FGF-2-induced synovitis was prevented by systemic administration of 3 doses of the angiogenesis inhibitor PPI-2458 during the acute phase.
Our findings indicate that conversion of acute inflammation to chronic inflammation may be due to the stimulation of angiogenesis, and brief antiangiogenic treatment during the acute phase of synovitis may prevent its subsequent progression. Clinical studies will be needed to determine whether brief antiangiogenic treatment may reduce the burden of inflammatory joint diseases such as rheumatoid arthritis by facilitating the resolution of early synovitis.
确定在滑膜炎消退开始时血管生长是否会导致其随后持续存在,以及在持续性炎症开始时抑制这种血管生成是否会导致其随后消退。
通过向大鼠膝关节注射0.03%角叉菜胶和/或6皮摩尔成纤维细胞生长因子2(FGF-2)诱导炎症和血管生成。在滑膜炎诱导前1天至诱导后3天,隔天口服血管生成抑制剂PPI-2458(5毫克/千克)进行短期治疗。对照组包括未处理和接受赋形剂处理的大鼠。使用内皮细胞增殖指数测量滑膜血管生成,并通过测量关节肿胀和巨噬细胞百分比面积来确定炎症。数据以几何平均值(95%置信区间)表示。
向大鼠膝关节内注射0.03%角叉菜胶可产生急性滑膜炎,这与滑膜血管生成无关,且在29天内消退。注射FGF-2(6皮摩尔)可诱导滑膜血管生成而无明显滑膜炎。在注射角叉菜胶时用FGF-2刺激血管生成后,滑膜炎持续29天。在急性期全身给予3剂血管生成抑制剂PPI-2458可防止角叉菜胶/FGF-2诱导的滑膜炎持续存在。
我们的研究结果表明,急性炎症向慢性炎症的转变可能是由于血管生成的刺激,在滑膜炎急性期进行短期抗血管生成治疗可能会阻止其随后的进展。需要进行临床研究以确定短期抗血管生成治疗是否可通过促进早期滑膜炎的消退来减轻类风湿关节炎等炎性关节疾病的负担。